Infectious Diseases News

PHILADELPHIA--(BUSINESS WIRE)--AREXVY recommended for adults aged 50-59 at increased risk for severe RSV disease by US Advisory Committee on Immunization Practices...

PHILADELPHIA--(BUSINESS WIRE)--GSK’s 5-in-1 meningococcal vaccine PENMENVY receives positive recommendation from US Advisory Committee on Immunization Practices...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). This includes ABRYSVO® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug...

DUBLIN--(BUSINESS WIRE)--The "Cervical Dystonia - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report delivers an in-depth understanding of cervical dystonia, historical and forecasted epidemiology, as well as the trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan. The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed...

FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare (NASDAQ: ACHC) (“Acadia” or the “Company”) today announced that it will release its first quarter 2025 financial results on Monday, May 12, 2025, after the close of the market. Acadia will conduct a conference call with institutional investors and analysts on Tuesday, May 13, 2025, at 8:30 a.m. ET. A live broadcast of the conference call will be available at www.acadiahealthcare.com in the “Investors” section of the website. The webcast of the...

SAN DIEGO--(BUSINESS WIRE)--Today, Toragen, Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from its Phase 1 trial of TGN-S11, a small molecule inhibitor of the human papillomavirus (HPV) E5 oncogene protein, in patients with cancers associated with HPV. This Phase 1 trial was an open-label, non-randomized study in multiple cohorts of patients with relapsed, resistant,...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for PBGENE-HBV, the Company’s lead wholly owned in vivo gene editing program designed to cure chronic hepatitis B by eliminating cccDNA, the key source of replic...

MADISON, Wis.--(BUSINESS WIRE)--Promega technology will support a collaboration between Charles River and CEPI's Centralised Laboratory Network aimed at vaccine development....

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that plans are advancing to launch three new sample preparation instruments during 2025 and 2026 to expand and strengthen its portfolio for automated sample preparation. These systems are designed to deliver new levels of efficiency and sustainability for laboratories worldwide and address different customer segments: QIAsymphony Connect, which marks the next generation of the flagship QIAsym...

BELLINGHAM, Wash.--(BUSINESS WIRE)--TOKU-E introduces Pirlimycin Hydrochloride for food safety testing workflows....